# PULSAR in Systemic Therapy for Pancreatic Cancer

Source: https://onco.cc/trials/nct07269626/  
OnCo record `nct07269626` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Samsung Medical Center, now recruiting.

## Summary

PULSAR in Systemic Therapy for Pancreatic Cancer is a phase 2, interventional study registered as NCT07269626 by Samsung Medical Center, with a registry enrolment figure of 47 participants, started 2025-11-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: Personalized Ultrafractionated Adaptive Radiotherapy. Conditions listed: Locally Advanced Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Oligometastatic Pancreatic Ductal Adenocarcinoma. Primary outcome: progression-free survival at 1-year after enrollment; Progression-free survival; Local control (LC). Pancreatic eligibility wording from the registry: "* Histologically confirmed pancreatic ductal adenocarcinoma". Sites: South Korea. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07269626
- Phase: 2
- Setting: A Prospective Phase II Study of Systemic Therapy With Combined Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Pancreatic Cancer
- Sponsor: Samsung Medical Center
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT07269626: https://clinicaltrials.gov/study/NCT07269626

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07269626.json